Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

Alexander M. M. Eggermont; Marna G. Bouwhuis; Wim H. Kruit; Alessandro Testori; Timo ten Hagen; Antoine Yver; Christine Xu

首页> 外文期刊>Cancer Chemotherapy and Pharmacology >Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

【24h】

Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

机译：在一项随机化的III期临床试验中，接受了聚乙二醇化干扰素α-2b辅助治疗的切除的III期黑色素瘤患者中的聚乙二醇化干扰素α-2b的血清浓度（EORTC 18991）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose The EORTC 18991 trial assessed the effect of long-term adjuvant pegylated interferon (Peg-IFN) α-2b administered weekly in patients with lymph node-positive melanoma. Serum concentrations were analyzed to determine exposure to Peg-IFN α-2b.

机译：目的EORTC 18991试验评估了每周一次长期应用的聚乙二醇干扰素（Peg-IFN）α-2b在淋巴结阳性黑色素瘤患者中的疗效。分析血清浓度以确定暴露于Peg-IFNα-2b。

著录项

来源
《Cancer Chemotherapy and Pharmacology》 |2010年第4期|p.671-677|共7页
作者
Alexander M. M. Eggermont; Marna G. Bouwhuis; Wim H. Kruit; Alessandro Testori; Timo ten Hagen; Antoine Yver; Christine Xu;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Peginterferon alfa; 2b; Melanoma; Pharmacokinetics; Cytokines;

机译：聚乙二醇干扰素α;2b;黑色素瘤;药动学;细胞因子;

相似文献

外文文献
中文文献
专利

1. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). [J] . Eggermont AM, Bouwhuis MG, Kruit WH, Cancer chemotherapy and pharmacology. . 2010,第4期

机译：在一项随机III期试验（EORTC 18991）中，接受了聚乙二醇化干扰素α-2b辅助治疗的切除III期黑色素瘤患者的聚乙二醇化干扰素α-2b的血清浓度。
2. 5LB Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation [J] . M.G.Bouwhuis, S.Suciu, A.Testori, European Journal of Cancer Supplements . 2007,第6期

机译：5LB EORTC 18991 III期随机试验比较聚乙二醇干扰素α2b与观察性辅助疗法对黑色素三期患者自身抗体的预后价值
3. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma [J] . EggermontA.M.M., SuciuS., TestoriA., Journal of Clinical Oncology . 2012,第31期

机译：聚乙二醇干扰素α-2b辅助治疗的III期随机试验EORTC 18991的长期结果与切除的III期黑色素瘤的观察结果
4. Pegylated Interferons In the Adjuvant Treatment of Melanoma [C] . Dirk Schadendorf International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：在黑色素瘤的佐剂治疗中的聚乙二醇化干扰素
5. A comparison of methods for estimating survival probabilities in two stage phase III randomized clinical trials. [D] . Wang, Ying. 2009

机译：在两个阶段的III期随机临床试验中比较评估生存概率的方法。
6. Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB IIC and III Cutaneous Melanoma Patients: A Single Institution Randomized Study [O] . José Mordoh, María Betina Pampena, Mariana Aris, -1

机译：IIBIIC和III期皮肤黑色素瘤患者的CSF-470疫苗加芽孢杆菌卡介苗联合重组人粒细胞巨噬细胞集落刺激因子与中等剂量干扰素α2B辅助免疫治疗的II期研究研究
7. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial [O] . Eggermont, A M M, Suciu, S, Santinami, M, 2008

机译：聚乙二醇干扰素α-2b的辅助治疗与单独治疗III期黑色素瘤的观察：EORTC 18991的最终结果（一项随机III期试验）

Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

摘要

著录项

相似文献

相关主题

期刊订阅